Is renal impairment linked to increased transaminase changes from tigecycline?

Is renal impairment linked to increased transaminase changes from tigecycline

Renal impairment does not appear to drive changes in liver enzyme levels during tigecycline treatment. Pharmacokinetic data show that tigecycline clearance is unaffected by kidney function, and dosing adjustments are not recommended for patients with reduced renal function.

How do kidney problems affect tigecycline blood levels

Studies in subjects with severe renal impairment and end-stage renal disease on hemodialysis found no meaningful change in tigecycline exposure compared with healthy volunteers. Dose reduction is therefore unnecessary.

Do transaminase elevations occur more often when kidneys are impaired

Clinical trials and post-marketing reports have not identified a higher rate of ALT or AST elevations in patients with renal impairment. Transaminase increases remain tied to tigecycline exposure rather than kidney status.

What monitoring is advised for patients with both kidney and liver concerns

Baseline and periodic liver-function tests are recommended regardless of kidney status. Renal function should be tracked only to ensure standard dosing, not because it alters hepatic safety.

When does the tigecycline patent expire

The primary U.S. composition-of-matter patent for tigecycline expired in 2020, but secondary formulation patents extend market exclusivity until 2029 for certain products. [1]

Who makes generic tigecycline

Multiple manufacturers, including Teva, Mylan, and Fresenius Kabi, have launched generic tigecycline in the U.S. and Europe after patent expiry.

Can biosimilars or generics enter before full patent expiry

Only authorized generics or products under settlement agreements could launch before 2029; otherwise, remaining formulation patents block full generic competition until exclusivity ends.